68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label brain PET/CT (positron emission tomography/computed tomography) study
to investigate the diagnostic performance and evaluation efficacy of 68Ga-BNOTA-PRGD2 in
glioma patients. A single dose of nearly 111 MBq 68Ga-BNOTA-PRGD2 (≤40 µg BNOTA-PRGD2) will
be intravenously injected into patients in suspicion of glioma. Visual and semiquantitative
method will be used to assess the PET/CT images. Brain MRI with/without enhancement and
18F-FDG PET/CT will be performed for comparison. The postoperative pathology and integrin
αvβ3 and CD34 immunohistochemical stains will also be used for correlation.